Ask AI
ProCE Banner Series

Global Guidance and Regional Perspectives on Optimizing Molecular Profiling and Perioperative Management of Early-Stage NSCLC

Join us for this interactive, CME/EACCME-certified live webinar featuring global pathology and oncology expert perspectives on current and emerging strategies in molecular testing and immunotherapy and targeted therapy for early-stage NSCLC. Be sure to bring your questions for the live Q&A session with the expert panel.

  AMA
Who Should Attend

This activity is intended for global medical oncologists, thoracic oncologists, pulmonologists, thoracic surgeons, pathologists, molecular biologists, and other healthcare professionals who care for patients with early-stage NSCLC.

All Events

Global Guidance and Regional Perspectives on Optimizing Molecular Profiling and Perioperative Management of Early-Stage NSCLC

Upcoming Events

May

18

2026

12:00 PM - 1:30 PM Eastern Time (ET)

Virtual

Topics

Lung cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence at performing timely comprehensive molecular testing to select the optimal systemic treatment for each patient with early-stage NSCLC.

Target Audience
This activity is intended for global medical oncologists, thoracic oncologists, pulmonologists, thoracic surgeons, pathologists, molecular biologists, and other healthcare professionals who care for patients with early-stage NSCLC.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Educate colleagues on the rationale and clinical utility of comprehensive molecular testing in early-stage NSCLC
  • Perform molecular testing in each patient with early-stage NSCLC consistent with current evidence and local expert guidance
  • Develop processes to optimize interdisciplinary communication and collaboration to ensure timely and accurate interpretation of molecular testing for each patient with early-stage NSCLC
  • Recommend the optimal targeted therapy or immunotherapy for each patient with early-stage NSCLC, considering molecular testing results, patient/disease factors, evidence, and local expert guidance
  • Appraise emerging evidence and ongoing clinical trials of novel targeted therapies and immunotherapies and the clinical implications for management of early-stage NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191